BioSimilar – Page 2 – Policy & Medicine

High Expectations For New Biosimilars About to Hit Market

Biologic Exclusivity Provision Removed from USCMA Agreement

Study demonstrates impact of CME activities on clinician awareness of biosimilars

FDA Final Guidance on Demonstrating Biosimilar Interchangeability

Is FDA Guidance on Biosimilars Unconstitutional?

House Subcommittee Holds Fiery Hearing on Generic Competition

January MedPAC Recommendations: Rebates & Biosimilars

New Law Requires Biosimilar Deals to be Submitted to the FTC

FDA Holds Public Meeting on Biosimilar Action Plan

Biosimilars Rapidly Gain Market Share in EU